{"filings":[{"id":869956,"accession_number":"0000313143-26-000057","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2026-06-05T10:33:22+00:00","items":["7.01","9.01"],"status":"ready","headline":"Haemonetics combines Plasma and Blood Center segments into Apheresis; Hospital renamed MedSurg","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["The new Apheresis segment combines formerly separate Plasma and Blood Center segments, effective Q1 FY2027.","Hospital segment renamed MedSurg to better reflect underlying businesses, technologies, and markets.","Supplemental presentation includes historical quarterly reconciliations from Q1 FY2024 to Q4 FY2026.","FY2027 guidance recast under new segment structure; company not reaffirming or updating guidance.","Updates, if any, to be provided on Q1 FY2027 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97905,"accession_number":"0000313143-26-000031","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics announces Q4 and FY2026 results; financial details not provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued on May 7, 2026 for quarter and fiscal year ended March 28, 2026.","Specific financial figures are not included in the provided excerpt; refer to Exhibit 99.1.","The earnings release is furnished as Exhibit 99.1 to this Form 8-K for further detail."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97904,"accession_number":"0000313143-26-000023","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Haemonetics director Charles Dockendorff will not stand for re-election at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles J. Dockendorff, Board member since 2014, will not stand for re-election at the 2026 Annual Meeting.","He serves on the Audit Committee and the Governance and Compliance Committee.","His decision is not the result of any disagreement with the company.","He will continue as a director and in his committee roles until the 2026 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113098,"accession_number":"0000313143-26-000017","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Haemonetics repays $300M of 0.00% convertible notes at maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $300M principal of 0.00% Convertible Senior Notes due 2026 at maturity on March 2, 2026.","Funding came from cash on hand and borrowings under its revolving credit facility.","No holders exercised conversion rights prior to the maturity date.","Capped call transactions entered in connection with the notes expired upon maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113097,"accession_number":"0000313143-26-000014","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Haemonetics publishes 2024-2025 Corporate Responsibility Report","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Report covers environmental, social, and governance initiatives; no financial data included.","Disclosure posted on company website; no quantitative updates for investors.","No changes to previously provided financial guidance or operational outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113096,"accession_number":"0000313143-26-000009","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics reports Q3 results; specifics not available from provided text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated February 5, 2026, furnished as Exhibit 99.1 for Q3 and nine months ended December 27, 2025.","No financial figures were included in the available filing content for analysis.","Markets rely on full press release details for revenue, EPS, and segment performance."],"consensus_eps_estimate":null,"consensus_eps_actual":2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":987676000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113095,"accession_number":"0000313143-26-000003","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Haemonetics acquires Vivasure Medical for up to €185M; upfront €100M plus €85M earn-out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired all equity of Vivasure Medical, a Galway, Ireland-based developer of percutaneous vessel closure technology.","Upfront consideration of €100M, net €52M after deducting prior investments and loans.","Up to €85M in contingent consideration tied to sales growth and other milestones.","Transaction funded with available cash on hand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129503,"accession_number":"0000313143-25-000074","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics announces Q2 FY2026 results; no figures in provided text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["The company issued a press release on November 6, 2025 for its second quarter ended September 27, 2025.","First half fiscal 2026 results are also included in the release.","Specific financial results (revenue, EPS, etc.) are not available in the excerpt provided here."],"consensus_eps_estimate":null,"consensus_eps_actual":1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":648709000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146060,"accession_number":"0000313143-25-000056","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics reports Q1 FY2026 results; press release details not provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Haemonetics issued press release on Aug 7, 2025 for Q1 ended June 28, 2025.","The filing does not include the press release content; specific numbers not available.","Investors should reference the full press release for earnings details."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":321394000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146059,"accession_number":"0000313143-25-000047","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Haemonetics shareholders elect all nine director nominees, approve say-on-pay, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine nominees elected with 42.6-43.8M votes; broker non-votes 1.76M.","Advisory say-on-pay approved: 43.0M for, 585k against, 253k abstain.","Ernst & Young ratified as auditor for FY2026: 43.8M for, 1.5M against, 245k abstain.","Turnout 94.95% of 48.0M shares outstanding; no proposal failed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164372,"accession_number":"0000313143-25-000021","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Haemonetics approves restructuring $20M charges; targets $30M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Board approved market and regional alignment initiative in May 2025.","Expected aggregate restructuring charges of ~$20M, half severance, half other exit costs.","Savings of ~$30M annually expected by end fiscal 2027.","Q4 and FY 2025 earnings press released issued; no specific figures available in filing.","Charges will be cash outlays; initiative to continue through fiscal 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182131,"accession_number":"0000313143-25-000015","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Haemonetics appoints Frank Chan as EVP COO, promotes Roy Galvin to CCO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frank Chan appointed EVP COO effective April 7, 2025; oversees R&D, regulatory, global manufacturing & supply chain.","Roy Galvin promoted to EVP, Chief Commercial Officer effective immediately; adds Global Hospital business to his remit.","Chan's compensation: $550k base salary, 80% target bonus, $1.6M long-term equity award, plus $350k sign-on bonus.","Chan most recently President of Medtronic's Acute Care & Monitoring business; 25+ years experience.","Stewart Strong continues as President, Global Hospital through April 1, then advisor to CEO for transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182130,"accession_number":"0000313143-25-000011","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics issues Q3 FY2025 earnings press release; no details available in input","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing reports results for Q3 and nine months ended December 28, 2024, via press release.","Press release is furnished as Exhibit 99.1 but was not included in the provided text.","No specific financial figures, guidance, or business updates are extractable from the given input.","The filing is a standard 8-K under Item 2.02; no other material events reported."],"consensus_eps_estimate":1.1213,"consensus_eps_actual":2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":1030225000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182129,"accession_number":"0000313143-25-000006","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Haemonetics completes sale of whole blood assets to GVS for up to $67.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total cash consideration up to $67.8M: $45.3M upfront (adjusted) plus up to $22.5M contingent.","Contingent consideration tied to three-year sales growth and other milestones.","Transaction closed on January 13, 2025, as previously disclosed in December 2024 8-K.","Assets divested are within the Blood Center business unit's whole blood segment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182128,"accession_number":"0000313143-25-000003","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Haemonetics EVP Global Manufacturing to retire July 11, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Josep Llorens, EVP Global Manufacturing and Supply Chain, notified retirement effective July 11, 2025.","Llorens will remain in role during successor search and assist CEO with transition.","Company expresses gratitude for Llorens' contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198778,"accession_number":"0000313143-24-000066","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Haemonetics sells whole blood assets to GVS for $44.6M cash plus up to $22.5M earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $67.1M: $44.6M cash at close plus up to $22.5M contingent on sales growth and milestones.","Assets sold include whole blood collection, processing, and filtration portfolio, plus Covina, CA manufacturing facility and Tijuana, Mexico equipment.","Haemonetics retains its apheresis line for automated blood collection (platelets, plasma, red cells).","Transaction expected to close in Q1 2025, subject to customary closing conditions.","GVS (not publicly traded) is a filter-solutions manufacturer in healthcare and life sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198777,"accession_number":"0000313143-24-000060","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics announces Q2 FY2025 results; specific figures unavailable from provided filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company issued press release for quarter ended Sept 28, 2024 and first half of fiscal 2025.","No revenue, EPS, or segment data are included in the 8-K filing text provided.","Investors should consult the full press release for detailed financial results.","CEO Christopher A. Simon signed the Form 8-K on November 7, 2024."],"consensus_eps_estimate":1.0262,"consensus_eps_actual":1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":681683000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214810,"accession_number":"0000313143-24-000056","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Haemonetics CTO Anila Lingamneni to depart on November 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anila Lingamneni, EVP and Chief Technology Officer, will leave Haemonetics effective November 1, 2024.","No replacement for the CTO role has been announced.","The company expressed gratitude for Ms. Lingamneni's contributions and wished her success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214809,"accession_number":"0000313143-24-000053","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics reports Q1 FY2025 results; details in press release not provided","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed 8-K on August 8, 2024 for quarter ended June 29, 2024.","Press release attached as Exhibit 99.1 but text not included in this summary.","Specific financial figures (revenue, EPS) not available from given text."],"consensus_eps_estimate":null,"consensus_eps_actual":0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":336172000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214807,"accession_number":"0000313143-24-000047","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K/A","filed_at":"2024-07-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Haemonetics shareholders elect directors, approve executive pay and auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 9 director nominees elected with ~47.1M–47.6M votes each; no director received less than 46.8M for.","Advisory vote on executive compensation passed with 46.2M for, 1.46M against, 142k abstain.","Ratification of Ernst & Young as auditor for FY ending March 29, 2025: 47.74M for, 1.05M against.","Quorum of 48.9M shares (95.99% of outstanding) present at the July 25, 2024 meeting.","Amendment corrects clerical error in original 8-K regarding fiscal year reference in proposal 3 description."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214808,"accession_number":"0000313143-24-000044","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"All nine Haemonetics directors elected; say-on-pay and auditor ratification pass","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 95.99% (48.9M of 50.95M shares) represented at the July 25, 2024 annual meeting.","Each director nominee received >46.7M for votes; Christopher A. Simon led with 47.6M.","Advisory vote on executive compensation passed with 46.2M for, 1.5M against, 0.1M abstain.","Ratification of Ernst & Young LLP as independent auditor approved with 47.7M for, 1.0M against, 0.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233964,"accession_number":"0001104659-24-066056","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Haemonetics issues $700M in 2.50% convertible notes due 2029; used to repurchase 2026 notes and repay revolver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $700M (incl. $100M greenshoe) of 2.50% Convertible Senior Notes due June 1, 2029.","Used proceeds to repurchase $200M of 0% 2026 notes for $185.5M and repay $230M revolver balance.","Entered capped call transactions costing ~$88.2M with cap price $180.18 (100% premium over stock).","Initial conversion rate 8.5385 shares/$1,000 (~$117.12/share); notes redeemable from June 2027 if stock exceeds 130% of conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233963,"accession_number":"0001104659-24-064437","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Haemonetics prices $600M 2.50% convertible notes due 2029; to repurchase $200M of 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$600M 2.50% convertible senior notes due 2029 priced; initial conversion price ~$117.12/share (30% premium over $90.09 closing).","Concurrently repurchasing $200M aggregate principal of 0.00% 2026 notes for $185.5M cash in privately negotiated transactions.","Net proceeds estimated ~$584.8M; to repay $230M revolver, pay ~$75.6M for capped calls, and for general purposes.","Capped call transactions entered to offset dilution, with initial cap price $180.18/share (~100% premium).","Initial purchasers granted option to buy up to additional $100M principal amount of notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233962,"accession_number":"0001104659-24-063835","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Haemonetics announces $525M convertible senior notes offering due 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$525M principal amount of convertible senior notes due 2029, with option for additional $75M.","Notes accrue interest semi-annually, mature June 1, 2029; settlement in cash up to $1,000 principal, then stock/cash.","Proceeds to fund capped call transactions to offset dilution, plus working capital and general corporate purposes.","Offering only to qualified institutional buyers under Rule 144A; notes not registered under Securities Act.","Option counterparties may enter derivative transactions affecting HAE stock price around pricing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233961,"accession_number":"0000313143-24-000015","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics announces Q4 and FY2024 financial results; details not available in this filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated May 9, 2024, reports results for quarter and fiscal year ended March 30, 2024.","Specific financial figures (EPS, revenue, guidance) are not included in the provided filing text.","The release may contain material operational updates, but cannot be summarized without exhibit content."],"consensus_eps_estimate":null,"consensus_eps_actual":2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":1309055000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233960,"accession_number":"0000950103-24-006128","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Haemonetics enters $1B credit agreement; $250M term loan, $750M revolver due 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $250M senior unsecured term loan retires existing term loan under 2022 credit agreement.","Revolving credit facility increased by $330M to $750M from prior $420M.","Maturity extended to April 30, 2029, with quarterly amortization increasing over term.","Interest rate: Adjusted Term SOFR plus spread of 1.125% to 1.750% based on leverage ratio.","Financial covenants: max leverage 4.00x (4.50x after material acquisition), min interest coverage 3.50x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233959,"accession_number":"0000313143-24-000012","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Haemonetics completes acquisition of Attune Medical (Advanced Cooling Therapy)","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed on April 1, 2024; terms consistent with March 5, 2024 8-K disclosure.","Attune Medical (Advanced Cooling Therapy) acquired; no deal value or financing details disclosed.","Press release issued confirming completion; no material changes from prior announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251935,"accession_number":"0000313143-24-000009","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Haemonetics to acquire Attune Medical for $160M upfront; device complements EP portfolio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash $160M plus contingent consideration based on sales growth and milestones.","Attune Medical's ensoETM device reduces esophageal injury during cardiac ablation; revenue $22M in 2023, doubled YoY.","Transaction expected to close in Q1 fiscal 2025 (April-June 2024) subject to customary conditions.","Haemonetics expects immediate accretion to revenue and earnings growth; financed via cash and revolver."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251934,"accession_number":"0000313143-24-000006","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics reports Q3 FY2024 results; specific figures not available in provided text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed an 8-K on Feb 8, 2024, announcing Q3 and nine-month results for period ended Dec 30, 2023.","Press release issued as Exhibit 99.1 but full financial details are not included in the provided filing text.","Investor should refer to the complete press release for specific revenue, EPS, and segment data."],"consensus_eps_estimate":null,"consensus_eps_actual":1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":965765000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269467,"accession_number":"0000313143-23-000060","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Haemonetics closes acquisition of OpSens Inc.","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Acquisition of OpSens Inc. closed on December 12, 2023, as previously announced.","Terms consistent with those disclosed in October 2023 8-K filings.","Press release issued on closing date; no new financial details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269466,"accession_number":"0000313143-23-000056","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics reports Q2 FY2024 results; specific figures not included in filed document","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Earnings release dated November 2, 2023 for quarter and first half ended September 30, 2023.","Press release was furnished as Exhibit 99.1 but its text was not provided in the filing.","No financial metrics, guidance changes, or segment data available for analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":629515000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269464,"accession_number":"0000313143-23-000051","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K/A","filed_at":"2023-10-12T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Haemonetics to acquire OpSens for $2.90/share cash via arrangement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Haemonetics to acquire all outstanding shares of OpSens via plan of arrangement under Quebec Business Corporations Act.","Consideration of $2.90 per share in cash; termination fee of $12.075 million payable by OpSens in certain circumstances.","Support and voting agreements with certain shareholders to vote in favor of the arrangement resolution.","Transaction subject to shareholder approval, Quebec Superior Court order, and regulatory clearances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269465,"accession_number":"0000313143-23-000048","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Haemonetics to acquire OpSens for CAD $2.90/share in cash, expected close by March 31, 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Haemonetics (HAE) will pay CAD $2.90 per share for all OpSens common shares via a plan of arrangement under Québec law.","Closing conditions include 2/3 shareholder vote, HSR and Investment Canada approvals, court order, and no material adverse effect.","OpSens directors and officers owning ~4.75% of shares have agreed to vote in favor via voting agreements.","If OpSens terminates for a superior proposal or changes recommendation, it pays Haemonetics a CAD $12.075M termination fee.","The transaction must close by March 31, 2024, with an automatic 75-day extension if regulatory approvals are not yet obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286437,"accession_number":"0000313143-23-000039","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics Q1 fiscal 2024 results announced; press release text not available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing states Haemonetics issued a press release on Aug 8, 2023 for Q1 ended July 1, 2023.","No specific financial metrics (revenue, EPS, guidance) are provided in the extracted text.","Confidence low: cannot confirm actual performance numbers from this filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":311332000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286436,"accession_number":"0000313143-23-000037","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Haemonetics elects Diane M. Bryant to board, shareholders approve amended LTIP with 2.97M new shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Diane M. Bryant elected to board effective 8/4/2023; former CEO of NovaSignal, ex-COO of Google Cloud, 32-year Intel veteran.","Bryant appointed to Compensation and Technology Committees; receives standard non-employee director comp with ~$200k annual equity award.","Shareholders approved amended 2019 LTIP authorizing 2,966,231 new shares for issuance and extending plan to August 3, 2033.","All eight director nominees elected; advisory say-on-pay approved with 44.96M for; Ernst & Young ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306328,"accession_number":"0000313143-23-000010","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics reports Q4 and FY2023 results; specific figures not available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Reported financial results for quarter and fiscal year ended April 1, 2023.","Press release issued on May 11, 2023, but no financial details provided in filing.","Unable to extract revenue, EPS, or segment performance from available text."],"consensus_eps_estimate":null,"consensus_eps_actual":2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":1168660000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325492,"accession_number":"0000313143-23-000004","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics Q3 fiscal 2023 adjusted EPS $0.82, revenue $298.1M; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $298.1M (+2.1% reported, -0.1% organic); GAAP EPS $0.37, adjusted EPS $0.82 vs $0.73 prior year.","Plasma revenue up 3% reported but down 5% organic; Hospital revenue up 12% reported (+7% organic).","Fiscal 2023 revenue guidance raised to $1.195B-$1.205B; adjusted EPS guidance raised to $3.45-$3.55.","Nine-month revenue $891.2M (+5.2% reported, +5.9% organic); operating cash flow $157.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":864244000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343231,"accession_number":"0000313143-22-000059","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics files 8-K for Q2 FY2023 results; filing lacks specific financial figures","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company issued press release for Q2 ended October 1, 2022 and first half FY2023 results.","Filing only references Exhibit 99.1; actual financial data not included in provided text.","Confidence in event detail is low due to absence of numbers in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":558943000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343230,"accession_number":"0000313143-22-000056","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-10-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Haemonetics appoints Maryanne Farris as VP, Chief Accounting Officer; GC Michelle Basil continues","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maryanne Farris joined as VP, Chief Accounting Officer and principal accounting officer on Oct 17, 2022.","James D'Arecca remains EVP, CFO and principal financial officer; no change in his role.","Company and EVP/GC Michelle Basil mutually agreed to terminate a June 2022 transition letter; she continues in her current role.","Ms. Farris previously served as Chief Accountant at Azenta, Inc. and is a CPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359782,"accession_number":"0000313143-22-000050","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics reports Q1 FY2023 earnings; no financial details in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated August 10, 2022, covering quarter ended July 2, 2022, was furnished as exhibit.","No specific revenue, EPS, or segment data are available from the provided filing text.","Registrant is Haemonetics Corporation (HAE), a Massachusetts corporation trading on NYSE."],"consensus_eps_estimate":null,"consensus_eps_actual":0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":261458000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359781,"accession_number":"0000313143-22-000045","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Haemonetics names CFO James D'Arecca as principal accounting officer following controller's departure","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["James C. D'Arecca, EVP/CFO, assumes principal accounting officer role effective Aug 5, 2022, replacing departing controller Dan Goldstein.","2022 annual meeting held Aug 5 with 94.1% quorum; all nine director nominees elected with majority support.","Shareholders approved say-on-pay (43.98M for, 2.71M against) and ratified Ernst & Young as auditor (47.09M for, 1.16M against).","Vote totals show high approval for most directors; Charles Dockendorff and Ellen Zane received the most withhold votes at 5.96M and 3.27M, respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359780,"accession_number":"0000313143-22-000042","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Haemonetics enters amended credit agreement: $280M term loan, $420M revolver, maturity extended to June 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $420M revolving credit facility (up from $350M) and $280M term loan to replace existing term loan.","Maturity extended by two years to June 15, 2025; quarterly amortization begins at 2.5% then 5%.","Interest: Adjusted Term SOFR plus 1.125%–1.750% credit spread based on leverage ratio.","Financial covenants: max leverage 3.50x (4.00x post-acquisition), min interest coverage 4.00x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378614,"accession_number":"0000313143-22-000032","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"EVP & General Counsel Michelle Basil to depart Haemonetics by Oct 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michelle L. Basil, EVP and General Counsel, will transition from Haemonetics effective October 31, 2022.","She will remain in her role through the Retention Date to ensure a seamless transition while a successor is sought.","Under the Agreement, she will receive a $500,000 retention bonus if she stays through Oct 31 without resignation or cause termination.","Her base salary continues unchanged and outstanding equity awards vest through Retention Date; she will not receive FY2023 short-term incentive bonus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378613,"accession_number":"0000313143-22-000026","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-05-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Haemonetics principal accounting officer Dan Goldstein to depart Aug 9, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dan Goldstein, VP Corporate Controller and Principal Accounting Officer, will leave on August 9, 2022.","Goldstein will remain in his current role while the company searches for his successor.","No reason for departure stated; no replacement named yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378612,"accession_number":"0000313143-22-000020","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics issues Q4 FY2022 earnings press release; details not available in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated May 10, 2022, furnished as Exhibit 99.1, covers Q4 and full year ended April 2, 2022.","Specific financial results (revenue, EPS, guidance) are not included in the 8-K or appended exhibit text provided.","No material updates beyond the fact of the earnings release can be confirmed from the filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":993196000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396888,"accession_number":"0000313143-22-000015","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Haemonetics appoints James D'Arecca as CFO effective April 11, 2022; Burke to retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James D'Arecca appointed CFO effective April 11, 2022; William Burke steps down as CFO on that date.","D'Arecca previously CFO at TherapeuticsMD; prior roles at Allergan, Bausch & Lomb, Merck, PwC.","Compensation: $525k base salary, 75% target bonus, $1.1M LTI target, $400k sign-on bonus.","Initial equity grant valued at $600k: 50% RSUs, 50% options, vesting 25% annually over 4 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396887,"accession_number":"0000313143-22-000011","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-02-15T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"President of Global Plasma and Blood Center Chad Nikel to leave Haemonetics on March 2, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chad Nikel, President of Global Plasma and Blood Center, will depart Haemonetics effective March 2, 2022.","No replacement has been announced; the company expressed gratitude for his contributions.","The filing provides no reason for the departure and no successor is named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396886,"accession_number":"0000313143-22-000006","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics announces Q3 FY2022 results; no figures in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing reports Q3 and nine-month results for period ended Jan 1, 2022.","Press release (Exhibit 99.1) is referenced but its content is not provided in the filing text shown.","Specific revenue, EPS, or guidance numbers are absent from the available document."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":728194000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415840,"accession_number":"0000313143-21-000050","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Haemonetics CFO Burke to retire June 2022; retention bonus up to 50% of base salary","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["CFO William P. Burke to retire in June 2022; will remain in role and assist transition until then.","Retention bonus: 25% of base salary if new CFO starts before Apr 2, 2022; 50% if after.","Burke also to receive pro rata FY2023 bonus if retained through June 30, 2022.","Company issued Q2 FY2022 earnings press release (no financial details available in this filing)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433446,"accession_number":"0000313143-21-000043","cik":313143,"company_name":"HAEMONETICS CORP","ticker":"HAE","form_type":"8-K","filed_at":"2021-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Haemonetics reports Q1 FY2022 results; details not available in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed 8-K on Aug 11, 2021 for Q1 ended July 3, 2021 results.","Press release issued but not included in provided text; specific figures unknown.","Event type is earnings; no guidance or segment data presented in filing body.","Confidence low due to missing exhibit details; refer to full filing for numbers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":228528000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3052152111.0490727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-11T23:59:59+00:00|433446"}